Medicine
Riastap 2600 mg/100 mL injection
Riastap 2600 mg/100 mL injection is a prescription medicine containing Fibrinogen human for subcutaneous use, marketed by CSL Behring, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
When stored at temperatures of 2-8°C (36-46°F), RIASTAP is stable for the…
Key facts
- Active ingredient (INN)
- Fibrinogen human
- Brand
- Riastap
- Strength
- 2600 mg/100 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 vial of 100 mL
- Marketing authorisation holder
- CSL Behring
- Manufacturer
- CSL Behring
- Origin register
- US FDA, United States
- Storage
- When stored at temperatures of 2-8°C (36-46°F), RIASTAP is stable for the period indicated by the expiration date on the carton and vial label (up to 60 months). Do not freeze. Protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B02BB01 Fibrinogen
- HS code (indicative)
- 3002.12Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 January 2009
- Identifiers
- RxCUI 831506, 831509DailyMed set ID 903dc8d0-39da-462c-9dac-004e0c7a26ccNDC 63833-892Application BLA125317
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 100 mL in 1 vial, glass | 63833-892-51 | CSL Behring | 16 January 2009 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Fibrinogen human
Clinical summary
Fibrinogen human is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia, among other approved uses. MedsAcross supplies Fibrinogen human for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Fibrinogen humanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RiaSTAP prescribing information (CSL Behring) · U.S. National Library of Medicine, DailyMed
Need Riastap 2600 mg/100 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.